Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Arcadia Biosciences Inc
RKDA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.1530
0.008
5.52%
Dern. MÀJ: Oct 20, 6:40 PM
$0.1517
0.00666
4.59%
Get Report
Aperçu
Actualités
Prévisions de résultats
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Privacy Manager
Arcadia Biosciences Financials
Arcadia Biosciences (RKDA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Arcadia Biosciences Q2 EPS $(2.09) Up From $(3.26) YoY, Sales $1.443M Down From $1.455M YoY
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(2.09) per share. This is a 35.89 percent increase over losses of $(3.26) per share from the same period last year. The company reported $1.443 million in
Benzinga Newsdesk
PRO
Arcadia Biosciences Q1 EPS $(2.11) Misses $(0.80) Estimate, Sales $1.100M Miss $1.600M Estimate
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(2.11) per share which missed the analyst consensus estimate of $(0.80) by 163.75 percent. This is a 211.05 percent decrease over earnings of $1.90 per
Benzinga Newsdesk
PRO
Arcadia Biosciences Q4 EPS $(0.97) Misses $(0.66) Estimate, Sales $901.000K Miss $1.400M Estimate
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.66) by 46.97 percent. This is a 67.45 percent increase over losses of $(2.98) per share
Benzinga Newsdesk
PRO
Arcadia Biosciences Q3 EPS $0.63, Sales $1.302M Miss $1.900M Estimate
Benzinga Newsdesk
PRO
Arcadia Biosciences Q2 EPS $(3.26) Misses $(0.79) Estimate, Sales $1.455M Miss $1.600M Estimate
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(3.26) per share which missed the analyst consensus estimate of $(0.79) by 312.66 percent. This is a 517.95 percent decrease over earnings of $0.78 per
Benzinga Newsdesk
PRO
CORRECTION: Arcadia Biosciences Q1 EPS $1.90 Beats $(0.76) Estimate, Sales $1.20M Miss $1.60M Estimate
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $(0.76) by 350 percent. This is a 206.74 percent increase over losses of $(1.78) per share
Benzinga Newsdesk
